Skip to contents

Charles Nicholas Serhan, PhD, DSc
Director, CETRI, Brigham and Women's Hospital
Head of the Department of Oral Medicine, Infection, and Immunity, Harvard Medical School

Brigham and Women's Hospital
Department of Anesthesiology, Perioperative and Pain Medicine
75 Francis Street
Boston, MA 02115

Research Location: Harvard New Research Building

Email: cserhan@partners.org
Research Email: cnserhan@bwh.harvard.edu

Edit Profile


Research Narrative:

Research in the Serhan Laboratory focuses on structural elucidation of bioactive small molecules that activate the resolution of acute inflammation. Our overall mission is “To identify novel mediators, pathways, and cellular targets critical in promoting resolution of inflammation and reperfusion tissue injury and their relation to human disease.” Our studies currently focus on structural elucidation of novel molecules and pathways that serve as pro-resolving and/or endogenous anti-inflammatory chemical signals.

We elucidated several new families of lipid-derived, local-acting chemical mediators, coined the Resolvins and Protectins, and most recently Maresins, that stimulate resolution of inflammatory responses. We also designed novel therapeutic approaches using these structures as biotemplates. New therapeutic approaches built with the knowledge of these signaling pathways could be more potent, selective and better tolerated since they are based on structures naturally evolved in these processes. Several of these new designer therapeutics have already been shown to be effective in human disease.


Honors/Awards:
2016 Laureate, Ross Prize in Molecular Medicine. 2017 Lifetime Achievement Award, Eicosanoid Research Foundation 2018 Rous-Whipple Award from the American Society for Investigative Pathology 2018 Gaddum International Award Lecture & Prize, British Pharmacological Society 2019 Honorary Lifetime Award, Society for Leukocyte Biology, for excellence in leukocyte biology research : 2018 pharmacology, 2019 and 2020 Highly Cited Researcher from Clarivate, top 0.1% in immunology.

Additional News: